Choose Your Country or Region

Cilengitide trifluoroacetate

Name: Cilengitide trifluoroacetate
Brand: Selleck Chemicals
SKU: S7077
Rating: 5 (52 reviews)

Catalog No.S7077 Synonyms: EMD 121974, NSC 707544

For research use only.

Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Selleck's Cilengitide trifluoroacetate has been cited by 52 publications

Purity & Quality Control

Choose Selective Integrin Inhibitors

Related Compound Libraries

Biological Activity

Description

Targets

αvβ3 receptor ^[1] (Cell-free assay)	αvβ5 receptor ^[2] (Cell-free assay)
4.1 nM	79 nM

In vitro

Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. ^[1] Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and ﬁbrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively. ^[2] Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. ^[3] 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. ^[4] Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

G28	MVPGeY5kfGmxbjDBd5NigQ>?	Mk\sOVAh\|rypL33s	NHPBS\|M{OC94MD:xNlAhdWmw		MlHObY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGZCUyxiU4LjJIFv\CCDa4S=	MnP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
HMEC-1	MonISpVv[3Srb36gRZN{[Xl?	MoHtNlAwPDBxNkCg{txoN22u			Mn3XbY5pcWKrdIOgSmFMKGGwZDDTdoPDqA>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
G44	MUjBdI9xfG:\|aYOgRZN{[Xl?	MmLlNU82NzVyIN88[{9udA>?	NUG1PJhiOjRiaB?=		MoPlbY5lfWOnczDhdI9xfG:\|aYO=	M3zMOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
G28	M3;JVGFxd3C2b4Ppd{BCe3OjeR?=	M{LYWFEwPS93MDFOwIcwdWx?	MXKyOEBp		MX;pcoR2[2W\|IHHwc5B1d3Orcx?=	M2Tp[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
G44	NWrkfplkWHKxbHnm[ZJifGmxbjDBd5NigQ>?	NXG0eI5JOS93L{WwJO69\y:vbB?=	MmXrNlQwPDhxN{KgbC=>		MlrpbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NFvlTmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G28	MWHQdo9tcW[ncnH0bY9vKEG\|c3H5	MnXNNU82NzVyIN88[{9udA>?	NVXUPWVGOjRxNEivO\|IhcA>?		NGPHSJNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NHvQOZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
HMEC-1	NEnI[nVCeG:ydH;zbZMhSXO\|YYm=	NH7mVJgyNzVxNUCg{txoN22u	Mn\JNlQhcA>?		NFLWfmtqdmS3Y3XzJIFxd3C2b4Ppdy=>	NGrOfII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
HMEC-1	NF74V3RRem:uaX\ldoF1cW:wIFHzd4F6	Moe1NU82NzVyIN88[{9udA>?	NFzxNoozPC92OD:3NkBp		MnjzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M2P3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
HMEC-1	NFGweW1HfW6ldHnvckBCe3OjeR?=	MmrRNU82NzVyIN88[{9udA>?	Mk[1NlQhcA>?		NGK2[VVqdmS3Y3XzJIEh\G:\|ZTDk[ZBmdmSnboSg[IV1[WOqbXXueOKh	NVrPOHM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
LNT-229	NW\OTFlNTnWwY4Tpc44hSXO\|YYm=	MlHvNE4yNzFxMUCg{txO	NGTJb4gzPCCq		NGrRVHVqdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUG3NUc,OTl{MkGxO\|E9N2F-
T98G	NEfKVWRHfW6ldHnvckBCe3OjeR?=	NVvMepBjOC5zL{GvNVAh\|ryP	MlLGNlQhcA>?		NEHPc5BqdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M3vITFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKxNVcyLz5zOUKyNVE4OTxxYU6=
LN-18	M3LIUWZ2dmO2aX;uJGF{e2G7	MkPhNE4yNzFxMUCg{txO	M4fJe\|I1KGh?		MnnJbY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	Ml7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO\|EoRjF7MkKxNVcyRC:jPh?=
LN-308	Mn7nSpVv[3Srb36gRZN{[Xl?	M13BUlAvOS9zL{GwJO69VQ>?	NUDnb2JKOjRiaB?=		MXPpcZBicXK\|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUG3NUc,OTl{MkGxO\|E9N2F-
U87MG	MnrDSpVv[3Srb36gRZN{[Xl?	MkDrNE4yNzFxMUCg{txO	MoLWNlQhcA>?		NWnzfJk6cW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	Moj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO\|EoRjF7MkKxNVcyRC:jPh?=
U87	Mm\3SpVv[3Srb36gRZN{[Xl?	NVrBd\|BYOC1{NTFOwIcwdUx?	MoDwNVIhcMLi		MmXCbY5lfWOnczDheZRweGijZ4mg[I9{\SCmZYDlcoRmdnSueR?=	M4nETVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N\|Q{Lz5{MUe4PFM1OzxxYU6=
U251	MkDVSpVv[3Srb36gRZN{[Xl?	NXHmXGxZOC1{NTFOwIcwdUx?	NFXp[28yOiCqwrC=		MWnpcoR2[2W\|IHH1eI9xcGGpeTDkc5NmKGSncHXu[IVvfGy7	M1rpOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N\|Q{Lz5{MUe4PFM1OzxxYU6=
U87	M3nx[2Fxd3C2b4Ppd{BCe3OjeR?=	NXr1bnBEOjVizsznM41N	NHXySmYzPC92ODDo		NXnYVI5{cW6mdXPld{BieG:ydH;zbZMh[XRiNEigbEB{cWewaX\pZ4FvfGy7	NF3uXZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe4PFM1Oyd-MkG3PFg{PDN:L3G+
U251	Ml3rRZBweHSxc3nzJGF{e2G7	NXP0[oxmOjVizsznM41N	M3PXblI1NzR6IHi=		NYXGNoZWcW6mdXPld{BieG:ydH;zbZMh[XRiNEigbEB{cWewaX\pZ4FvfGy7	NVmwTFU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO\|g5OzR\|PD;hQi=>
U87	NV;i[YpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkL4NE0zPSEQvHevcWw>	Mmj3NE01QCCq		NYniW2xzcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	MlHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OEizOFMoRjJzN{i4N\|Q{RC:jPh?=
U251	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnJfmM5OC1{NTFOwIcwdUx?	MWOwMVQ5KGh?		MnfEbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	M{jiXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N\|Q{Lz5{MUe4PFM1OzxxYU6=
U251MG	MoLaRZBweHSxc3nzJGF{e2G7	MmCwNUDDvU1?	M{\sPFQ5KGh?		NEfL[\|VqdmS3Y3XzJIFxd3C2b4Ppdy=>	NUDPS2RoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVQ5ODdpPkKzN\|U1QDB5PD;hQi=>
U87MG	M2G0WGFxd3C2b4Ppd{BCe3OjeR?=	Mk\xNUDDvU1?	NFX5bIE1QCCq		M3jSeIlv\HWlZYOgZZBweHSxc3nz	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3NEiwO{c,OjN\|NUS4NFc9N2F-
U251MG	NInqfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\BRXBmOC1{NTFOwG0>	NUPmeYlKOjRxNEigbC=>		NXznVnlPcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3NEiwO{c,OjN\|NUS4NFc9N2F-
U87MG	NIHxSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7tcGcxNTJ3IN88US=>	MnnKNlQwPDhiaB?=		NWGzUZNJcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	NWr3XHlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVQ5ODdpPkKzN\|U1QDB5PD;hQi=>
MCF-7	MXLBdI9xfG:\|aYOgRZN{[Xl?	NUfXcGhvOC1{MDFOwG0>	MXi0PEBp		NVrmZmZFcW6mdXPld{BieG:ydH;zbZM>	MnTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUOxNFIoRjJ2MUWzNVAzRC:jPh?=
T-47D	M1zGemFxd3C2b4Ppd{BCe3OjeR?=	MUSwMVIxKM7:TR?=	M4XjW\|Q5KGh?		M1LzSolv\HWlZYOgZZBweHSxc3nz	M{Lh[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUWzNVAzLz5{NEG1N\|ExOjxxYU6=
MCF-7	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXmwMVIxKM7:TR?=	MoTaPVYhcA>?		MnHubY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M3jKNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUWzNVAzLz5{NEG1N\|ExOjxxYU6=
T-47D	Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIKwcXkxNTJyIN88US=>	NEK0fXE6PiCq		MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NUGweY92RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVMyODJpPkK0NVU{OTB{PD;hQi=>
FaDu	NEC2S3hCeG:ydH;zbZMhSXO\|YYm=	M37NcFI2yqEEtV5CpC=>	NFm5Wmo1QMLiaNMg		M1XsWolv\HWlZYOgZZBweHSxc3nz	NUH0XWxbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
CAL27	M1n5emFxd3C2b4Ppd{BCe3OjeR?=	NFjLdGgzPcLiwsXNxsA>	NH3O[mg1QMLiaNMg		MVXpcoR2[2W\|IHHwc5B1d3Orcx?=	MmLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
SCC25	M37SS2Fxd3C2b4Ppd{BCe3OjeR?=	MY[yOeKhyrWPwrC=	NHThbWc1QMLiaNMg		M122T4lv\HWlZYOgZZBweHSxc3nz	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
FaDu	M{Ttdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWOz[Y11Pi5{NfMAl\|IxOMLiwsXN	MmfTO\|IhcA>?		MULy[ZN2dHS\|IH3v[IVz[XSnLDDkc5NmNWSncHXu[IVvfCCpcn;3eIghcW6qaXLpeIlwdg>?	MnLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
CAL27	MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfCbIQ3NjJ34pETNlAxyqEEtV2=	MmnJO\|IhcA>?		Mnf4doV{fWy2czDtc4RmemG2ZTyg[I9{\S2mZYDlcoRmdnRiZ4Lve5RpKGmwaHnibZRqd25?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
SCC25	NUnOe2xNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYe2MlI26oDVMkCwxsDDvU1?	M4W1TFczKGh?		NWnVWllSemW\|dXz0d{Bud2SncnH0[Uwh\G:\|ZT3k[ZBmdmSnboSg[5Jwf3SqIHnubIljcXSrb36=	NVfk[Hc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
H28	NVzRZ496S2WubDDWbYFjcWyrdImgRZN{[Xl?	NEHQOmUyKG6PLUKwNEDPxE1?	MoDVO\|IhcA>?		MXvk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NInjcXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
MM05	Mkj5R4VtdCCYaXHibYxqfHliQYPzZZk>	M1rlcVEhdk1vMkCwJO69VQ>?	NVLSbJNWPzJiaB?=		NWHzWVA4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NH\S[FA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
MSTO-211H	MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MWexJI5ONTJyMDFOwG0>	M1P1e\|czKGh?		NIizWG5l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NFrne\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
REN	MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NV\p[\|I3OSCwTT2yNFAh\|ryP	MYS3NkBp		NV\rTIJE\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NWfrc2JRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PVUzPzRpPkK0OVk2Ojd2PD;hQi=>
LN-308	MWTGeY5kfGmxbjDBd5NigQ>?	NX;POWxoOTEkgJpOwI0>	MYCyOEBp	MV7EUXNQyqB?	MYjy[YR2[2W\|IFHoVkBxem:2ZXnuJIxmfmWuczDhcoQhTFKHIILldI9zfGW{IHHjeIl3cXS7	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjVyMEC1Okc,OjZ3MECwOVY9N2F-
HaCaT	NUP0[2puTnWwY4Tpc44hSXO\|YYm=	MXqxNQKBkc7:bR?=	MWC0PEBp	NY[4b\|lSTE2VT9Mg	NHrUN45z\WS3Y3XzJHRITi4QskNCpI1TVkFiZYjwdoV{e2mxbh?=	NXnZepU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
S-24	MmK5SpVv[3Srb36gRZN{[Xl?	MnXtNU8yOOLCid88cS=>	MUeyOEBp	MlXZSG1UV8Li	M1n5dJJm\HWlZYOgSHJGKHKncH;yeIVzKGGldHn2bZR6	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjVyMEC1Okc,OjZ3MECwOVY9N2F-
ZH-161	NWjqVWtQTnWwY4Tpc44hSXO\|YYm=	NWDWbXNZOS9zMPMAje69dQ>?	MVOyOEBp	NGXMfIZFVVORwrC=	MWLy[YR2[2W\|IFTSSUBz\XCxcoTldkBi[3Srdnn0fS=>	MoOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MECwOVYoRjJ4NUCwNFU3RC:jPh?=
LN-308	MXLGeY5kfGmxbjDBd5NigQ>?	NYHy[5J{OS9zMD:xNFDjiIoQvH2=	NXyxcJo6OjRiaB?=	M1vNZWROW00EoB?=	NXTzZmF4emWmdXPld{BFWkVicnXwc5J1\XJiYXP0bZZqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjVyMEC1Okc,OjZ3MECwOVY9N2F-
M21	MnHKSpVv[3Srb36gZZN{[Xl?		Mn33NUBpeg>?		NIfYbGlDcW6maX7nJIFn\mmwaYT5JJRwKGmwdHXndolvKGGucHjhek9j\XSjMzDo[ZRmem:maX3ldkBqdiCqdX3hckBOOjFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBqdnSnZ4Lpck1u\WSrYYTl[EBpfW2jbjDNNlEh[2WubDDh[Ihme2mxbjD0c{B3cXS{b37lZ5RqdiCjZoTldkAyKGi{IHnuJJBz\XOnbnPlJI9nKE2wQ3yyMEBKSzVyIE2gNE4xODB2IN88UU4>	M4n0V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{WzPFE1Lz5{Nke1N\|gyPDxxYU6=
HEK293T	NXXkN\|JpTnWwY4Tpc44h[XO\|YYm=		NHPSSlEzKGi{cx?=		NWf4[206SmmwZHnu[{Bi\m[rbnn0fUB1dyC\|b3z1ZoxmKHS{dX7jZZRm\CCqdX3hckBz\WOxbXLpcoFvfCCIYz30ZYdo\WRiYXzwbIFX[mW2YUOgZY5lKGmwdHXndolveyC5ZYLlJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHPvcZBmfGm2aX;uJGVNUVODLXzpb4Uh[XO\|YYmsJGlEPTBiPTCwMlAxODVzIN88UU4>	NHznRZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVA6Pid-MkSwPVUxQTZ:L3G+
HT-29	NF;pZmdHfW6ldHnvckBie3OjeR?=		NX\4NXNmOiCqcoO=		MUHBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGmwdHXndolvKGGucHjhWoJmfGF3IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhVNTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuIHHkbIV{cW:wIITvJJZqfHKxbnXjeIlvKGGodHXyJFIhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTJizszNMi=>	Mk\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|NUG1PVQoRjJ6M{WxOVk1RC:jPh?=
HEK293	NIjpN\|dHfW6ldHnvckBie3OjeR?=		MX2yJIhzew>?		MVTBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGmwdHXndolvKGGucHjhWoJmfGF\|IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDh[Ihme2mxbjD0c{BncWK{aX7v[4VvKGGodHXyJFIhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOjJizszNMi=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MUW5OEc,Ojh\|NUG1PVQ9N2F-
SKOV3	NVfkOW5ETnWwY4Tpc44h[XO\|YYm=		MVKyJIhzew>?		NVzqOnFLSW62YXfvcol{fCCjY4Tpeol1gSCjdDDpcpRm\3KrbjDhcJBp[V[kZYThN4FteGijVnLleIE2KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPLU3Y{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKGGmaHXzbY9vKHSxIH\pZpJqdm:pZX6gZYZ1\XJiMjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6zO{DPxE1w	M1fzdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WxOVk1Lz5{OEO1NVU6PDxxYU6=
U87MG	MnKwSpVv[3Srb36gZZN{[Xl?	MUixNFAhdk1?	M4TyS\|I1KGi{cx?=		M4r5VWlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdFU{KGGlY4XteYxifGmxbjDheEAyODBibl2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3S=	Ml30QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	NUDldZVFTnWwY4Tpc44h[XO\|YYm=	Moe2NVAxKG6P	M3XC[lI1KGi{cx?=		MmTNTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMh[WOldX31cIF1cW:wIHH0JFExOCCwTTDh[pRmeiB{NDDodpMhcW5icILld4Vv[2Vib3[gUWROOiCrbnjpZol1d3JiboX0cIlvNTNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=>	MlT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	M4OxfWZ2dmO2aX;uJIF{e2G7	NUmzRmdFOTByIH7N	NGTkZWMzPCCqcoO=		MnHFTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMh[WOldX31cIF1cW:wIHH0JFExOCCwTTDh[pRmeiB{NDDodpMhcW5icILld4Vv[2Vib3[gUWROOiCrbnjpZol1d3JiboX0cIlvNTNiYX7kJG1FVTRiaX7obYJqfG:{IGPKMVE4OjJ3NUCgZpkhX2W\|dHXyckBjdG:2IH3leIhw\A>?	NIr6NY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O\|U{ODN:L3G+
U87MG	MkjNSpVv[3Srb36gZZN{[Xl?	NEO2NnQyODBibl2=	MYm4JIhzew>?		NWrvU\|RuUW6qaXLpeIlwdiCxZjDhcJBp[V[kZYThN{BqdnSnZ4LpckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBOTE1{IH3SUmEh\XiycnXzd4lwdiCjdDCxNFAhdk1iYX\0[ZIhQCCqcoOgbY4heHKnc3XuZ4Uhd2ZiTVTNNkBqdmirYnn0c5IhdnW2bHnuMVMh[W6mIF3EUVQhcW6qaXLpeI9zKFOMLUG3NlI2PTBiYomgVnQuWEOUIH3leIhw\A>?	NFLyOFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O\|U{ODN:L3G+
U87MG	MU\GeY5kfGmxbjDhd5NigQ>?	M1vSV\|ExOCCwTR?=	NIDybGwzPCCqcoO=		M4XX[GlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gVHVOSSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDifUBTXC2SQ2KgcYV1cG:m	M17XSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N\|A{Lz5{OUe3OVMxOzxxYU6=
U87MG	MkLqSpVv[3Srb36gZZN{[Xl?	NFewdVMyODBibl2=	MlvwNlQhcHK\|		NGDFOnZKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJHBWVUFibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkAzPCCqcoOgbY4heHKnc3XuZ4Uhd2ZiTVTNNkBqdmirYnn0c5IhdnW2bHnuMVMh[nliUmStVGNTKG2ndHjv[C=>	Mn[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	NIrTPWpHfW6ldHnvckBie3OjeR?=	NVfkZ2RROTByIH7N	NE\BcWIzPCCqcoO=		M1jnVGlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gVHVOSSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDpckBxemW\|ZX7j[UBw\iCPRF20JIlvcGmkaYTvdkBUUi1zN{KyOVUxKGK7IGLUMXBEWiCvZYToc4Q>	NXXYW2dwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	M2Hrc2Z2dmO2aX;uJIF{e2G7	NX7YSZpwOTByIH7N	M3\iXlI1KGi{cx?=		NIj4WpdKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJHBWVUFibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkAzPCCqcoOgbY4heHKnc3XuZ4Uhd2ZiTVTNNkBqdmirYnn0c5IhdnW2bHnuMVMh[W6mIF3EUVQhcW6qaXLpeI9zKFOMLUG3NlI2PTBiYomgVnQuWEOUIH3leIhw\A>?	M3r3blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N\|A{Lz5{OUe3OVMxOzxxYU6=
U87MG	NWP0NXl2TnWwY4Tpc44h[XO\|YYm=	MXSxNFAhdk1?	M1HDelI1KGi{cx?=		MknHTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwNlEhdVKQQTDlfJBz\XO\|aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiYomgVnQuWEOUIH3leIhw\A>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG	MojpRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MnPENVAxKG6P	NUXyO\|VSPzJiaILz		NW\XUGVFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BifCBzMECgcm0h[W[2ZYKgO\|IhcHK\|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIJ6KE2WUzDhd5NigQ>?	NFrSOWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O\|U{ODN:L3G+
U87MG	NH3QSpdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	NHLPOIsyODBibl2=	NVuybJp3PzJiaILz		Mke5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXOEfNS{Bk\WyuczDheEAyODBibl2gZYZ1\XJiN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJG1FVTJiaX7obYJqfG:{IH71eIxqdi1\|IHHu[EBOTE12IHnubIljcXSxcjDTTk0yPzJ{NUWwJIJ6KE2WUzDhd5NigQ>?	NVjlNnhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	M1Lwe2NmdGxiY4njcIUh[XO\|YYm=	MoXoNVAxKG6P	MWSyOEBpenN?		MYHD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzBxR{GgdIhie2ViYYSgNVAxKG6PIHHmeIVzKDJ2IHjydy=>	Mm\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	MoPERY51cS2rbo\hd4l3\SCjc4PhfS=>	MXGxNEB2VQ>?	M3X3R\|I1KGi{cx?=		NYfOS2xrSW62aT3pcpZie2m4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDVPFdOTyClZXzsd{BifCBzMDD1UUBi\nSncjCyOEBpenNiYomgeJJidnO5ZXzsJIF{e2G7	NUTKbXV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	M2Dw[WFvfGlvaX72ZZNqfmViYYPzZZk>	M{Txe\|ExKHWP	M2CyRVI1KGi{cx?=		M1y1emFvfGlvaX72ZZNqfmViYXP0bZZqfHliaX6gbJVu[W5iVUi3UWch[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGmwIIDy[ZNmdmOnIH;mJG1FVTJiaX7obYJqfG:{IH71eIxqdi1\|IHHu[EBOTE12IHnubIljcXSxcjDTTk0yPzJ{NUWwJIJ6KHS{YX7ze4VtdCCjc4PhfS=>	NXfme4lqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	pFAK / p-AKT ; GLI1	19114005 31366904
Immunofluorescence	VE-cadherin / β3 integrin	19212436
Growth inhibition assay	Cell number	24153102

In vivo

Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field). Cilengitide treatment results in prolonged survival of the mice bearing melanoma xenografts M21 compared with control treatment group. (36.5 vs 17.3 days). ^[5] Cilengitide can augment the therapeutic benefit associated with cytotoxic agents including chemotherapy and radiation therapy in tumor models. Cilengitide (250 mg/dose) alone does not alter tumor growth of breast cancer xenografts when compared with untreated mice, but combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 mg/dose) increases efficacy of treatment, with the cure rate for mice that receives only RIT increasing from 15 to 53%. CMRIT significantly increases apoptosis of tumor and endothelial cells 5 days, and decreases tumor proliferation. ^[6]

Protocol (from reference)

Kinase Assay:^[2]	Integrin-binding competition assay: Recombinant soluble integrins are immobilized, and peptides, which are serially diluted in Tris-buffered saline (TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl₂, 1 mM MgCl₂ 10 μM MnCl₂, 20 mM Tris-HCl; pH 7.4), are added in parallel with biotinylated vitronectin (to 1μg/mL). After a 3-h incubation at 37℃ and washing with Tris–buffered saline, bound ligand is detected by incubation with an antibiotin alkaline phosphatase-conjugated antibody (BioRad) followed by development with p-nitrophenyl phosphatase substrate. The reaction is stopped by the addition of NaOH and the color intensity read at 405 nm.
Cell Research:^[3]	Cell lines: Human microvascular endothelial cell line HMEC-1 Concentrations: 1-50 μg/mL Incubation Time: 3 days Method: HMEC-1 (1×10⁴ per well) are seeded on uncoated 48 well plates and incubated in medium containing 4% FCS with Cilengitide. After incubation for 72 hours at 37℃, cells are trypsinized and counted. (Only for Reference)
Animal Research:^[5]	Animal Models: Human glioblastoma xenografts U87 MG Dosages: 100μg Administration: Daily i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	100 mg/mL (142.31 mM)
	Water	8 mg/mL (11.38 mM)
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	702.68
Formula	C₂₉H₄₁F₃N₈O₉
CAS No.	199807-35-7
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N.C(=O)(C(F)(F)F)O

Download Cilengitide trifluoroacetate SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01517776	Terminated	Drug: Cilengitide\|Drug: Temozolomide	Gliomas	Martin-Luther-Universität Halle-Wittenberg\|Merck KGaA Darmstadt Germany	January 2012	Phase 2
NCT01118676	Completed	Drug: cilengitide radiochemotherapy	Locally Advanced Non Small Cell Lung Cancer (NSCLC)*	Institut Claudius Regaud\|Merck KGaA Darmstadt Germany	March 2010	Phase 1

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?

Answer:
S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.

Question 2:
Is Cilengitide a TFA salt?

Answer:
S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):